Name: | infliximab |
---|---|
PubChem Substance ID: | 17396768 |
Synonyms: |
Remicade; Infliximab; Infliximab (genetical recombination) (JAN); Infliximab (genetical recombination); D02598; Remicade (TN)
|
Name: | infliximab |
---|---|
Name (isomeric): | DB00065 |
Drug Type: | biotech |
Synonyms: |
Ig gamma-1 chain C region
|
Brand: | Remicade (Centocor Inc), Remicade |
Category: | Immunomodulatory Agents, Immunosuppressive Agents |
CAS number: | 170277-31-3 |
Indication: | To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis. |
---|---|
Pharmacology: |
Infliximab is a chimeric human-murine anti-human tumor necrosis factor (TNF) monoclonal antibody. It binds to tumor necrosis factor alpha (TNFa) and inhibits binding of TNFa with its receptors. This reduces production of pro-inflammatory cytokines such as interleukins (IL) 1 and 6. This also limits leukocyte migration and expression of adhesion mol...
show more » |
Mechanism of Action: |
Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa. Neutralization of the biological activity of TNFa leads...
show more » |
Biotransformation: | Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production |
Half Life: | 9.5 days |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|